Published in Lab Business Week, March 11th, 2007
Both DelSite Biotechnologies and ElSohly Laboratories have Cooperative Research and Development Agreements (CRADAs) with the National Cancer Institute (NCI). Whereas DelSite's CRADA covers the development of a nasal powder vaccine for Human Papillomavirus (HPV), ElSohly's CRADA covers an anticancer drug that has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week